CLIENT: US-based biopharmaceutical company
TARGET: specialty psychiatry market in the Russian Federation
ISSUE: the Client planned to choose an optimal commercial model of entering the Russian market with its own structure and products
OUR SOLUTION:  Complex research of the psychiatric market in Russia;  detailed description of formulary system and prescribing landscape via qualitative research among prescribers, KOLs, patients, manufacturers and regulatory authorities;  development of commercial model with calculation of set-up and operational costs
CLIENT VALUE: Timely and unbiased full-scale dossier on psychiatric market for further decision making with involvement of the board of directors
ISSUE: analyze adequacy of company’s strategy and sustainability of future development
OUR SOLUTION:  The analysis of the Target's strategy, investment and business plan for expansion of production capacities;  Analysis of the sustainability of the Target’s competitiveness and profitability;  Analysis of existing and planned product portfolios;  Study of the intercompany goods and cash flows;  Transfer pricing and tax arrangements analysis;  Study of the quality of the management team, organizational structure and systems
CLIENT VALUE: Comprehensive study of internal and external Target’s environment from the “outside” that was accepted by the investor for further (successful) decision regarding long-term capital investment
ISSUE: Client wanted to hold negotiations with an international drug procurement agency and to establish partnership in the supply of ARV medicines for Ukrainian patients.
OUR SOLUTION:  HIV epidemiology and burden of disease assessment in Ukraine;  market capacity analysis;  procurement portfolio of HIV drugs in Ukraine;  Pricing & Reimbursement analysis of HIV market in Ukraine;  Mapping of further legal issues
CLIENT VALUE: Full-scale marketing dossier on HIV medicines market in Ukraine. Expertise in procurement procedures and P&R mechanisms. Understanding of the cooperation
potential with international procurement agency. Timeline of further steps to do
“big pharma” company
ISSUE: the Client faced a patent expiry risks in several CEE/CIS markets and had a strong need in expansion of its portfolio with branded generics. Generic manufacturer had been bought before and the Client was searching for optimal scenarios to apply acquired portfolio in each country of the region.
OUR SOLUTION:  Existing portfolio detailed analysis;  Survey of treatment patterns and promotion practices;  Risk assessment of acquired portfolio entry into Ukrainian pharmaceutical market;  Brand plan for every new product
CLIENT VALUE: Appropriate set of opportunities and risks per each potential branded generic access to Ukrainian market